Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
BAXTER INTERNATIONAL INC (BAX) reported revenue of $2.96B and net income of $126.00M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BAXTER INTERNATIONAL INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.96B | $2.70B | $2.97B | $2.84B | $2.81B | $2.62B | $2.75B | $2.70B | $2.69B | $2.49B |
| Cost of revenue | $1.93B | $1.81B | $2.40B | $1.88B | $1.82B | $1.76B | $1.79B | $1.67B | $1.66B | $1.53B |
| Gross profit | $1.03B | $891.00M | $577.00M | $950.00M | $991.00M | $861.00M | $959.00M | $1.03B | $1.03B | $961.00M |
| Operating income | $217.00M | $66.00M | -$729.00M | $172.00M | $191.00M | $58.00M | -$435.00M | $155.00M | $179.00M | $115.00M |
| Net income | $126.00M | -$15.00M | -$1.13B | -$46.00M | $91.00M | $126.00M | -$512.00M | $140.00M | -$314.00M | $37.00M |
| Research & development | $129.00M | $139.00M | $126.00M | $118.00M | $134.00M | $140.00M | $211.00M | $129.00M | $130.00M | $120.00M |
| Weighted-average diluted shares | shares 518.00M | shares 515.00M | Unavailable | shares 514.00M | shares 514.00M | shares 514.00M | Unavailable | shares 512.00M | shares 511.00M | shares 510.00M |
| Pretax income | $158.00M | -$6.00M | -$756.00M | $121.00M | $133.00M | -$3.00M | -$521.00M | $69.00M | $117.00M | $46.00M |
| Income tax expense | $23.00M | $11.00M | $279.00M | $172.00M | $11.00M | -$67.00M | -$33.00M | $8.00M | $22.00M | $40.00M |
| Diluted EPS | $0.24 | $-0.03 | Unavailable | $-0.09 | $0.18 | $0.25 | $-1.00 | $0.27 | $-0.61 | $0.07 |
| Selling, general & administrative | $735.00M | $728.00M | $761.00M | $708.00M | $718.00M | $703.00M | $761.00M | $754.00M | $723.00M | $729.00M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.15B | $2.02B | $1.97B | $1.73B | $1.69B | $2.29B | $1.76B | $1.42B | $1.57B | $2.83B |
| Total assets | $19.79B | $19.85B | $20.06B | $21.07B | $21.05B | $21.30B | $25.78B | $26.68B | $26.31B | $27.79B |
| Current assets | $6.99B | $6.85B | $6.87B | $6.93B | $6.75B | $7.04B | $8.85B | $8.86B | $8.59B | $9.40B |
| Total liabilities | $13.61B | $13.83B | $13.95B | $13.85B | $13.75B | $14.25B | $18.76B | $18.73B | $18.60B | $19.55B |
| Current liabilities | $3.59B | $3.69B | $2.97B | $3.78B | $2.94B | $3.48B | $6.51B | $6.20B | $6.13B | $6.36B |
| Total equity incl. NCI | $6.18B | $6.02B | $6.10B | $7.21B | $7.29B | $7.05B | $7.02B | $7.94B | $7.71B | $8.24B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $2.26B | $2.32B | $2.23B | $2.46B | $2.38B | $2.17B | $2.05B | $2.10B | $2.98B | $2.99B |
| Accounts receivable | $1.86B | $1.70B | $1.86B | $1.78B | $1.77B | $1.65B | $1.68B | $1.73B | $2.64B | $2.52B |
| Goodwill | $4.89B | $4.90B | $4.93B | $5.40B | $5.40B | $5.34B | $5.28B | $5.78B | $6.00B | $6.43B |
| Long-term debt | Unavailable | Unavailable | $9.47B | Unavailable | Unavailable | Unavailable | $10.37B | $10.44B | $10.44B | $11.09B |
| Accounts payable | $1.03B | $1.09B | $999.00M | $953.00M | $995.00M | $963.00M | $968.00M | $841.00M | $1.25B | $1.33B |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $285.00M | $213.00M | $584.00M | $237.00M | $217.00M | -$193.00M | $488.00M | $253.00M | $115.00M | $163.00M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | -$117.00M | -$133.00M | -$198.00M | -$111.00M | -$115.00M | $3.26B | -$205.00M | -$164.00M | -$91.00M | -$166.00M |
| Financing cash flow | -$31.00M | -$11.00M | -$147.00M | -$81.00M | -$762.00M | -$3.23B | $141.00M | -$146.00M | -$936.00M | -$140.00M |
| Net change in cash | $137.00M | $51.00M | $240.00M | $40.00M | -$608.00M | -$118.00M | $334.00M | -$16.00M | -$934.00M | -$168.00M |
| Stock-based compensation | $33.00M | $10.00M | $37.00M | $35.00M | $35.00M | $10.00M | $39.00M | $38.00M | $20.00M | $17.00M |
| Common dividends paid | $5.00M | $5.00M | $87.00M | $87.00M | $87.00M | $87.00M | $147.00M | $148.00M | $148.00M | $147.00M |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $239.00M | $237.00M | $240.00M | $237.00M | $257.00M | $247.00M | $245.00M | $254.00M | $227.00M | $271.00M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 34.9% | 33.0% | 19.4% | 33.5% | 35.3% | 32.8% | 34.8% | 38.3% | 38.3% | 38.6% |
| Operating margin | 7.3% | 2.4% | -24.5% | 6.1% | 6.8% | 2.2% | Unavailable | 5.7% | 6.6% | 4.6% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 1.1% | 0.4% | 1.2% | 1.2% | 1.2% | 0.4% | Unavailable | 1.4% | 0.7% | 0.7% |
| Current ratio | 1.95x | 1.85x | 2.31x | 1.84x | 2.30x | 2.02x | 1.36x | 1.43x | 1.40x | 1.48x |
| Revenue YoY growth | 5.3% | 2.9% | 8.0% | 5.0% | 4.3% | 5.4% | 0.9% | 3.8% | 4.0% | 2.0% |
| Net margin | 4.3% | -0.6% | -37.9% | -1.6% | 3.2% | 4.8% | -18.6% | 5.2% | -11.7% | 1.5% |
| R&D / revenue | 4.4% | 5.1% | 4.2% | 4.2% | 4.8% | 5.3% | Unavailable | 4.8% | 4.8% | 4.8% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 14.6% | Unavailable | Unavailable | 142.1% | 8.3% | Unavailable | Unavailable | 11.6% | 18.8% | 87.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BAX in the interactive workspace to inspect any figure back to its filing.
Source filings
Reconciliation checks needing review
6 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
Operating, investing and financing flows differ from the reported change in cash by 90000000, beyond tolerance 4880000.00.
Operating, investing and financing flows differ from the reported change in cash by 39000000, beyond tolerance 2530000.00.
Operating, investing and financing flows differ from the reported change in cash by 54000000, beyond tolerance 4390000.00.